Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Codexis, Inc. (CDXS) Guidance & Earnings Results

On 2026-08-11 Codexis, Inc. reaffirmed guidance: "FY2026: total revenues $72M-$76M, gross margin high 60%…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CDXSCodexis, Inc.Follow CDXS — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
140.2M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
11 Aug 26ReaffirmedFY2026: total revenues $72M-$76M, gross margin high 60% range · full year
7 May 26ReaffirmedFY2026 revenue guidance $72-76M · full year
11 Mar 26RaisedFY2026 revenue guidance $72M-$76M · full year

Codexis, Inc. — questions

What guidance did Codexis, Inc. give?
On 2026-08-11: "FY2026: total revenues $72M-$76M, gross margin high 60% range"
When does Codexis, Inc. report earnings?
Codexis, Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from Codexis, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.